To the full analysis
Globus Medical stock: growth
GMEDGlobus Medical reported $2.94B in revenue for fiscal 2025, up 16.7% on the prior year, up 30.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.5%
per year from 2009 to 2025, per share 13.5%
Earnings (Annual rate)
16.2%
per year from 2009 to 2025, per share 13.2%
Free cash flow (Annual rate)
33%
per year from 2009 to 2025, per share 29.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2009 | |
|---|---|---|---|
| Revenue | 30.1% | 18.4% | 16.5% |
| Revenue per share | 22.1% | 14.3% | 13.5% |
| Earnings | 39.4% | 16.9% | 16.2% |
| Earnings per share | 30.8% | 12.8% | 13.2% |
| Free cash flow | 34.2% | 23.5% | 33.0% |
| Free cash flow per share | 26.0% | 19.3% | 29.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2009 | $254.34M | $48.73M | $6.12M |
| 2010 | $288.2M | $54.46M | $58.99M |
| 2011 | $331.48M | $60.78M | $53.92M |
| 2012 | $385.99M | $73.83M | $51.84M |
| 2013 | $434.46M | $68.61M | $69.79M |
| 2014 | $474.37M | $92.49M | $54.42M |
| 2015 | $544.75M | $112.78M | $71.2M |
| 2016 | $563.99M | $104.34M | $130.98M |
| 2017 | $635.98M | $107.35M | $108.23M |
| 2018 | $712.97M | $156.47M | $121.95M |
| 2019 | $785.37M | $155.21M | $101.23M |
| 2020 | $789.04M | $102.29M | $135.14M |
| 2021 | $958.1M | $149.19M | $219.38M |
| 2022 | $1.02B | $190.17M | $104.42M |
| 2023 | $1.57B | $122.87M | $165.23M |
| 2024 | $2.52B | $102.98M | $405.21M |
| 2025 | $2.94B | $537.9M | $588.77M |
Revenue by segment
How Globus Medical, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Spine94%
- Emerging Technology6%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Share 2024 | |
|---|---|---|---|---|---|---|---|
| Spine | $738.38M | $748.45M | $876.78M | $926.7M | $1.45B | $2.37B | 93.9% |
| Emerging Technology | $46.99M | $40.6M | $81.32M | $96.14M | $120.22M | $154M | 6.1% |
| Total revenue | $785.37M | $789.04M | $958.1M | $1.02B | $1.57B | $2.52B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.